Impact of Insulin Resistance on HCV Treatment Response and Impact of HCV Treatment on Insulin Sensitivity Using Direct Measurements of Insulin Action

• Autores: Danielle Brandman, Peter Bacchetti, Claudia Ayala, Jacquelyn Maher, Mandana Khalili
• Localización: Diabetes care, ISSN-e 0149-5992, Vol. 35, Nº. 5, 2012, págs. 1090-1094
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Insulin resistance, as measured by surrogate markers, is associated with lower response to hepatitis C virus (HCV) therapy and may improve with HCV eradication. We prospectively evaluated the impact of directly measured insulin resistance and abnormal glucose metabolism on achieving sustained virologic response (SVR) with HCV therapy and assessed whether SVR results in improved insulin sensitivity and fasting glucose. A total of 50 noncirrhotic, nondiabetic, HCV-infected patients (27 untreated, 23 treated with pegylated interferon/ribavirin, nonrandomized) underwent clinical and histologic evaluation and 75-g oral glucose tolerance test. Insulin sensitivity was assessed directly with insulin suppression test by measuring steady-state plasma glucose (SSPG) concentration during a 240-min infusion of octreotide, glucose, and insulin. Of the subjects, 43 had at least one follow-up evaluation. Patient characteristics were median age 48, 57% male, and 52% white. SVR was achieved in 61% (14 of 23) of treated subjects. SVR was independently associated with HCV genotypes 2 and 3 (odds ratio 8.8 [95% CI 1.2-61.7]) but was not strongly associated with insulin sensitivity. When controlling for elapsed time between measurements, being on interferon, and BMI, SSPG decreased by 36 mg/dL (-88 to 16) in those with SVR and decreased by 28 mg/dL (-93 to 38) in those without SVR, compared with the untreated group. BMI (coefficient 9.1 per 5 units; 95% CI 5.3-12.9) and interferon use (coefficient 56; 95% CI 6.8-105) were associated with SSPG. Insulin resistance does not appear to be strongly associated with SVR. HCV therapy may improve insulin resistance regardless of virologic response; however, BMI and interferon use were clearly associated with insulin resistance.

    Insulin resistance, as measured by surrogate markers, is associated with lower response to hepatitis C virus (HCV) therapy and may improve with HCV eradication. We prospectively evaluated the impact of directly measured insulin resistance and abnormal glucose metabolism on achieving sustained virologic response (SVR) with HCV therapy and assessed whether SVR results in improved insulin sensitivity and fasting glucose. A total of 50 noncirrhotic, nondiabetic, HCV-infected patients (27 untreated, 23 treated with pegylated interferon/ribavirin, nonrandomized) underwent clinical and histologic evaluation and 75-g oral glucose tolerance test. Insulin sensitivity was assessed directly with insulin suppression test by measuring steady-state plasma glucose (SSPG) concentration during a 240-min infusion of octreotide, glucose, and insulin. Of the subjects, 43 had at least one follow-up evaluation. Patient characteristics were median age 48, 57% male, and 52% white. SVR was achieved in 61% (14 of 23) of treated subjects. SVR was independently associated with HCV genotypes 2 and 3 (odds ratio 8.8 [95% CI 1.2-61.7]) but was not strongly associated with insulin sensitivity. When controlling for elapsed time between measurements, being on interferon, and BMI, SSPG decreased by 36 mg/dL (-88 to 16) in those with SVR and decreased by 28 mg/dL (-93 to 38) in those without SVR, compared with the untreated group. BMI (coefficient 9.1 per 5 units; 95% CI 5.3-12.9) and interferon use (coefficient 56; 95% CI 6.8-105) were associated with SSPG. Insulin resistance does not appear to be strongly associated with SVR. HCV therapy may improve insulin resistance regardless of virologic response; however, BMI and interferon use were clearly associated with insulin resistance.

    Ha solicitado la traducción automática simultánea del contenido seleccionado de nuestras bases de datos. Esta funcionalidad únicamente se ofrece para su comodidad y no intenta sustituir a la traducción por parte de un profesional. Mostrar rechazo de responsabilidad completo Ni ProQuest ni sus titulares asumen responsabilidad ni ofrecen garantía alguna con respecto a las traducciones. Las traducciones se generan automáticamente "TAL CUAL" y "SEGÚN DISPONIBILIDAD" y no permanecen en nuestros sistemas. PROQUEST Y SUS TITULARES RECHAZAN ESPECÍFICAMENTE SU RESPONSABILIDAD SOBRE CUALQUIER TIPO DE GARANTÍA EXPRESA O IMPLÍCITA, INCLUYENDO, ENTRE OTRAS, CUALQUIER GARANTÍA DE DISPONIBILIDAD, EXACTITUD, OPORTUNIDAD, TOTALIDAD, NO CUMPLIMIENTO, NO VIOLACIÓN, COMERCIABILIDAD O IDONEIDAD PARA UN PROPÓSITO PARTICULAR. El uso de las traducciones está sujeto a todas las restricciones de uso incluidas en su Acuerdo de Licencia de Productos Electrónicos. Al utilizar la funcionalidad de traducción acuerda a renunciar a cualquier tipo de reclamación contra ProQuest o sus titulares por el uso de dicha funcionalidad y cualquier escrito derivado de la misma. Ocultar rechazo de responsabilidad completo Traducciones con tecnología de LEC.

    Traducciones con tecnología de LEC.